Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$0.66.

  • 60 Degrees Pharmaceuticals' EPS (Basic) rose 8580.65% to -$0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.28, marking a year-over-year increase of 9963.41%. This contributed to the annual value of -$18.55 for FY2024, which is 6866.32% up from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' EPS (Basic) stood at -$0.66, which was up 8580.65% from -$1.18 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' EPS (Basic)'s 5-year high stood at $9.13 during Q3 2023, with a 5-year trough of -$31.32 in Q4 2023.
  • For the 4-year period, 60 Degrees Pharmaceuticals' EPS (Basic) averaged around -$5.33, with its median value being -$1.15 (2023).
  • Within the past 5 years, the most significant YoY rise in 60 Degrees Pharmaceuticals' EPS (Basic) was 159672.13% (2023), while the steepest drop was 437647.05% (2023).
  • 60 Degrees Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.7 in 2022, then tumbled by 4376.47% to -$31.32 in 2023, then skyrocketed by 84.69% to -$4.8 in 2024, then surged by 86.24% to -$0.66 in 2025.
  • Its EPS (Basic) stands at -$0.66 for Q3 2025, versus -$1.18 for Q2 2025 and -$1.56 for Q1 2025.